RESUMEN
Chimeric Antigen Receptor-modified(CAR)-T cells have become a new star living cell "drug" in the field of tumor immunotherapy, and five drugs have been available to the public since 2017. The favourable, rapid and efficient interaction of CAR-T therapy from bench to bedside has solved many new scientific problems, which remarkably expands the application field of multi-parameter flow cytometry (MFC). MFC participates the whole process of CAR-T preparation, functional evaluation, quality control, in vivo continuation evaluation, clinical efficacy and toxicity monitoring. New clinical problems caused by high-precision targeted therapy of CAR-T cells pose new challenges in using MFC for accurate tumor immunophenotyping, minimal residual disease monitoring, as well as the demands of comprehensively evaluation of the systematic immune function in different disease stages. In the era of targeted therapy, timely communication between laboratories and clinics is particularly important for obtaining accurate MFC results, which assists clinical individualized diagnosis and treatment.
RESUMEN
Objective To explore the correlation of minimal residual disease ( MRD) and ABC genes expression in acute myeloid leukemia ( AML) .Methods 52 de novo AML bone marrow samples were used to detect the expres-sion of ABCB1,ABCC1,ABCC4 andABCG2 by real-time PCR at diagnosis.Meanwhile, followed up these patients to monitor MRD with MFC at the points of finishing the first induction cause as well as the third ,the sixth and the ninth month after chemotherapy .Results The expression level of 4 ABC transporters among three MRD level de-tected after induction cause are correlated significantly with ABCB1(P<0.01), ABCC1(P<0.01), ABCC4(P<0.01) and ABCG2(P<0.01).Further more, after nine months follow-up, the patients whose MRD turned into positive again were detected a high ABC transports expression level , comparing with those MRD remained negative for nine months,which was of a statistically significance for ABCB1(P<0.05), ABCC1(P<0.05), ABCC4(P<0.01) and ABCG2(P<0.01).Conclusions A positive correlation of MRD and ABC transporters level in AML is found.
RESUMEN
Long time clinical results have showed that multiple myeloma (MM) patients who achieved complete remission (CR) had heterogeneous prognosis. Some patients who achieved CR relapsed in a short time, even died within 2 years after initial therapy, while other patients acquired long-term survival. With the emergence of minimal residual disease (MRD) assessment, rigorous personal therapy monitoring and accurate prognostic evaluation could be realized. MRD can monitor inside the bone marrow by multi-parameter flow cytometry, allele-specific oligonucleotide-based quantitative polymerase chain reaction and next-generation sequencing, as well as the external conditions of the bone marrow by sensitive imaging techniques. This article focuses on clinical benefit, characteristics of different monitoring methods and future direction of MRD in MM.